Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
US Department of Justice
Federal Trade Commission
Accenture
Farmers Insurance
Baxter
Cipla
AstraZeneca
Fish and Richardson

Generated: January 18, 2018

DrugPatentWatch Database Preview

Orion Pharma Company Profile

« Back to Dashboard

What is the competitive landscape for ORION PHARMA, and when can generic versions of ORION PHARMA drugs launch?

ORION PHARMA has two approved drugs.

There are three US patents protecting ORION PHARMA drugs.

There are ninety-eight patent family members on ORION PHARMA drugs in forty-one countries.

Summary for Orion Pharma
International Patents:98
US Patents:3
Tradenames:7
Ingredients:2
NDAs:2

Drugs and US Patents for Orion Pharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Orion Pharma STALEVO 75 carbidopa; entacapone; levodopa TABLET;ORAL 021485-005 Aug 29, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma COMTAN entacapone TABLET;ORAL 020796-001 Oct 19, 1999 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 50 carbidopa; entacapone; levodopa TABLET;ORAL 021485-001 Jun 11, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 75 carbidopa; entacapone; levodopa TABLET;ORAL 021485-005 Aug 29, 2008 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 150 carbidopa; entacapone; levodopa TABLET;ORAL 021485-003 Jun 11, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Orion Pharma

Paragraph IV (Patent) Challenges for ORION PHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg ➤ Subscribe 5/19/2009
➤ Subscribe Tablets 18.75 mg/75 mg/200 mg and 31.25 mg/125 mg/200 mg ➤ Subscribe 5/19/2009
➤ Subscribe Tablets 50 mg/200 mg/200 mg ➤ Subscribe 8/28/2008
➤ Subscribe Tablets 12.5 mg, 50 mg and 200 mg ➤ Subscribe 8/5/2008
➤ Subscribe Tablets 25/100/200 mg and 37.5/150/200 mg ➤ Subscribe 6/29/2007
➤ Subscribe Tablets 25/100/200 mg and 37.5/150/200 mg ➤ Subscribe 6/29/2007
➤ Subscribe Tablets 200 mg ➤ Subscribe 4/11/2007

International Patents for Orion Pharma Drugs

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Fuji
Argus Health
Baxter
Johnson and Johnson
Teva
Express Scripts
Dow
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot